Idiotype-derived peptide-Major Histocompatibility Complex (Id-pMHC) (Id-pMHC)

The Idiotype-derived peptide-Major Histocompatibility Complex (Id-pMHC) is a specialized antigen-presenting structure found on the surface of B-cell lineage cells, particularly in the context of B-cell malignancies like Multiple Myeloma and Follicular Lymphoma (Bogen et al., 1993). These complexes consist of peptides derived from the unique variable regions (idiotypes) of the clonal B-cell receptor (BCR) or secreted immunoglobulin, which are processed and loaded onto MHC Class I and Class II molecules (Lynch et al., 1985). Recognition of Id-pMHC by T-cell receptors (TCRs) is a cornerstone of tumor immunosurveillance, where CD4+ T cells recognize MHC II-presented idiotype peptides and CD8+ T cells recognize MHC I-presented counterparts (Corthay et al., 2005). Because the idiotype is unique to the malignant clone, these complexes serve as ideal tumor-specific antigens for precision immunotherapy. Therapeutic interventions, such as idiotype vaccines (e.g., BiovaxID) and TCR-engineered T cells, aim to stimulate or provide T cells that specifically target these complexes to eliminate cancerous cells while sparing healthy tissue (Schuster et al., 2011; Yi et al., 2000). However, challenges such as MHC downregulation by tumors and the inherent low immunogenicity of self-derived peptides remain significant hurdles in clinical application.

Other names

Idiotype-MHC complexB-cell receptor idiotype-derived peptide-MHCId-peptide-HLA complexTumor-specific idiotype antigenId-pMHC

Induction of idiotype-specific T-cell responses (CD4+ and CD8+) that recognize and eliminate malignant B cells presenting idiotype-derived peptides on MHC molecules.